|
| Clinical trial | Phase | Intervention | Status | Results |
|
| NN0281614 | 1 | A two-arm phase I study of IL-21 in metastatic melanoma | Completed | MTD established at 30 g/kg. Increased biomarkers (sCD25, perforin granzyme).
One PR that became CR 3 months later [136]. |
|
| NCT00617253 | 1/2 | Combination of rIL-21 and sunitinib in stage IV renal cell carcinoma patients | Completed | The tolerated dose of IL-21 (3 mg/kg) was too low and the study was discontinued [145]. |
|
| NCT00095108 | 1/2 | Study of IL-21 for metastatic malignant melanoma and metastatic kidney cancer | Completed | Melanoma: 1 CR and 11SD out of 24.
Renal cancer: 4PR and 13SD out of 19 [138] |
|
| NCT00389285 | 1/2 | Study of i.v. rIL-21 in combination with oral sorafenib for metastatic renal cell carcinoma | Completed | ORR 21% disease control rate 82% IL-21 plus sorafenib has antitumor activity and acceptable safety [146] |
|
| NCT00347971 | 1 | Study of rIL-21 in combination with Rituxan for relapsed/refractory low-grade B cell lymphoma | Completed | ORR 42% (3 CR and 5PR out of 19 patients) [143] |
|
| NCT00514085 | 2 | IL-21 in treating patients with metastatic or recurrent malignant melanoma | Completed | ORR 22.5% and 16 SD out of 40 patients [141] |
|
| NCT00336986 | 2 | Efficacy study of IL-21 to treat metastatic melanoma | Completed | ORR 8%, increased biomarkers [137] |
|
| NCT00523380 | 2 | Efficacy study of rIL-21 plus doxil in the treatment of ovarian cancer | Completed | No data available |
|
| NCT00601861 | 2 | Effect of rIL-21 on metastases in lymph nodes in melanoma skin cancer | Terminated | No data available |
|
| NCT01152788 | 2 | A randomized phase II study of rIL-21 versus dacarbazine in patients with metastatic or recurrent melanoma | Active, not recruiting | rIL-21 is comparable to DTIC in this patient population (4/30 = 13.3% 4/28 = 14.3%) [142] |
|
| NCT01489059 | 1 | Safety study of IL-21/ipilimumab combination in the treatment of melanoma | Completed | No data available |
|
| NCT01629758 | 1 | Safety study of IL-21/anti-PD-1 combination in the treatment of solid tumors | Active, not recruiting | No data available |
|
| NCT01787474 | 1/2 | IL-21-expanded NK cells for induction of acute myeloid leukemia (AML) | Recruiting | No data available |
|
